Merck & Co.
AWARDS
NEWS
Long COVID is loosely defined as COVID-19 symptoms that persist for longer than four weeks from an initial diagnosis. Here’s a look at the latest in long COVID research.
After a stint as head of a pharmaceutical company in China, Joseph Romanelli is returning to Merck as head of the human health international division.
AstraZeneca and Daiichi Sankyo reported that their supplemental Biologics License Application (sBLA) for Enhertu was granted Priority Review by the U.S. Food and Drug Administration.
The FDA granted Merck’s investigational 21-valent pneumococcal conjugate vaccine (V116) for IPD and pneumococcal pneumonia Breakthrough Therapy Designation.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
AstraZeneca has penned a deal with Harbour Biomed for its bispecific antibody HBM7022, which is intended to eliminate tumors in oncological patients.
JOBS
IN THE PRESS